References
- Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
- Geng D, Zheng L, Srivastava R, Velasco-Gonzalez C, Riker A, Markovic SN, Davila E. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res 2010; 70:7442-54; PMID:20807806; http://dx.doi.org/10.1158/0008-5472.CAN-10-0247
- Xiao H, Peng Y, Hong Y, Huang L, Guo ZS, Bartlett DL, Fu N, Munn DH, Mellor A, He Y. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. J Immunol 2013; 190:5866-73; PMID:23610140; http://dx.doi.org/10.4049/jimmunol.1203470
- Lu H. TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects. Front Immunol 2014; 5:83; PMID:24624132; http://dx.doi.org/10.3389/fimmu.2014.00083
- Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol 2013; 93:847-63; PMID:23475577; http://dx.doi.org/10.1189/jlb.1012501
- Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E. TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res 2015; 75:1959-71; PMID:25795705; http://dx.doi.org/10.1158/0008-5472
- Leigh ND, Bian G, Ding X, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity. PLoS One 2014; 9:e85587; PMID:24454895; http://dx.doi.org/10.1371/journal.pone.0085587
- Garaude J, Kent A, van RN, Blander JM. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012; 4:120ra16; PMID:22323829; http://dx.doi.org/10.1126/scitranslmed.3002868
- Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 2015; 21:2278-88; PMID:25695689; http://dx.doi.org/10.1158/1078-0432.CCR-14-2085